checkAd

    EQS-News  181  0 Kommentare CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

    Für Sie zusammengefasst
    • CureVac initiates Phase 2 study in seasonal influenza with GSK
    • Study focuses on improved immune responses against influenza B strain
    • Vaccine candidate modified to match all three WHO-recommended flu strains

    Issuer: CureVac / Key word(s): Study
    CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

    28.05.2024 / 13:00 CET/CEST
    The issuer is solely responsible for the content of this announcement.


    CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
     

    • Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strain
    • Study initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study in seasonal influenza
    • Composition of vaccine candidate changed to match all three WHO-recommended flu strains, following recommendation to exclude B/Yamagata lineage
       

    TÜBINGEN, Germany/BOSTON, USA – May 28, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced dosing of the first participant in a Phase 2 study of the multivalent seasonal influenza vaccine candidate developed in collaboration with GSK. The study will assess targeted optimizations for improved immune responses of the vaccine candidate against the relevant influenza B strain.

    This new Phase 2 study in the joint CureVac/GSK seasonal influenza program has been initiated following interim data from the Phase 2 part of the ongoing combined Phase 1/2 study in seasonal influenza reported on April 4, 2024. The reported data showed that among younger and older adults, serum hemagglutinin inhibition (HAI) geometric mean titers elicited by the vaccine candidate against influenza A strains numerically exceeded those of the applied licensed comparator vaccines consistently across all tested dose levels. For influenza B strains, serum HAI geometric mean titers were lower than those elicited by the licensed comparator vaccines across tested age groups and dose levels.

    Seite 1 von 4


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK Issuer: CureVac / Key word(s): Study CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK 28.05.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of …

    Schreibe Deinen Kommentar

    Disclaimer